Prognostic Biomarker Candidates Identified for Ovarian Cancer
|
By LabMedica International staff writers Posted on 25 Nov 2014 |
|
Image: Histopathology of ovarian serous papillary borderline tumor, intracystic, without surface cortical involvement (Photo courtesy of Brown University).
Two independent classes of novel candidate prognostic markers for ovarian cancer have been identified advancing efforts to develop targeted therapies for the disease.
An association of this often-deadly cancer has been made with the immune system and clarified the role of a class of immunogenic tumor antigens known as cancer testis (CT) antigens, as the immune system can potently inhibit the growth of cancer cells. These novel findings may enable development of a new strategy for identifying those patients most likely to benefit from particular targeted therapies.
Scientists at the Roswell Park Cancer Institute (Buffalo, NY, USA) establish novel associations between prognosis and the expression of immune-related genes through a focused screen utilizing publicly available high-throughput assays. The Cancer Genome Atlas (TCGA; Bethesda, MD, USA) is a biorepository study of high-grade serous ovarian cancers from multiple centers in the USA and relevant to their analysis, the study strictly included ovarian primaries and papillary serous histologies.
The team found preliminary evidence that some CT antigens are associated with survival when examined in concert with the five-gene signature. Fifteen of 64 immune-related genes were associated with survival of which five were reproduced in a validation set. The expression of these genes defines an immunoreactive (IR) subgroup of patients with a favorable prognosis. Phenotypic characterization of the immune compartment signal includes upregulation of markers of CD8+ T-cell activation in these patients.
Takemasa Tsuji, PhD, an assistant professor of Oncology and co-author of the study said, “CT antigens like the cancer-testis antigen NY-ESO-1 are readily recognized by the immune system and are therefore prime targets for cancer immunotherapies, so this work unveiling interaction between cancer and immune cells has real implications for our development of efficient immunotherapies at the Center for Immunotherapy. Determining patterns of both the immunological markers and CT antigens present in a women's tumor can lead the way to personalized medicine, an approach that uses the best combination of therapeutic modality and target antigen.” The study was published on November 7, 2014, in the journal Public Library of Science ONE.
Related Links:
Roswell Park Cancer Institute
The Cancer Genome Atlas
 Reagent.jpg)
An association of this often-deadly cancer has been made with the immune system and clarified the role of a class of immunogenic tumor antigens known as cancer testis (CT) antigens, as the immune system can potently inhibit the growth of cancer cells. These novel findings may enable development of a new strategy for identifying those patients most likely to benefit from particular targeted therapies.
Scientists at the Roswell Park Cancer Institute (Buffalo, NY, USA) establish novel associations between prognosis and the expression of immune-related genes through a focused screen utilizing publicly available high-throughput assays. The Cancer Genome Atlas (TCGA; Bethesda, MD, USA) is a biorepository study of high-grade serous ovarian cancers from multiple centers in the USA and relevant to their analysis, the study strictly included ovarian primaries and papillary serous histologies.
The team found preliminary evidence that some CT antigens are associated with survival when examined in concert with the five-gene signature. Fifteen of 64 immune-related genes were associated with survival of which five were reproduced in a validation set. The expression of these genes defines an immunoreactive (IR) subgroup of patients with a favorable prognosis. Phenotypic characterization of the immune compartment signal includes upregulation of markers of CD8+ T-cell activation in these patients.
Takemasa Tsuji, PhD, an assistant professor of Oncology and co-author of the study said, “CT antigens like the cancer-testis antigen NY-ESO-1 are readily recognized by the immune system and are therefore prime targets for cancer immunotherapies, so this work unveiling interaction between cancer and immune cells has real implications for our development of efficient immunotherapies at the Center for Immunotherapy. Determining patterns of both the immunological markers and CT antigens present in a women's tumor can lead the way to personalized medicine, an approach that uses the best combination of therapeutic modality and target antigen.” The study was published on November 7, 2014, in the journal Public Library of Science ONE.
Related Links:
Roswell Park Cancer Institute
The Cancer Genome Atlas
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent
Latest Molecular Diagnostics News
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
Channels
Clinical Chemistry
view channel
3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more.jpg "Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)")
POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more
Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
The conventional methods for measuring free cortisol, the body's stress hormone, from blood or saliva are quite demanding and require sample processing. The most common method, therefore, involves collecting... Read more
Molecular Diagnostics
view channel
Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
Alzheimer’s disease is well known for its slow development over many years, which typically leads to treatment interventions only after the disease has advanced to stages where it may be nearly impossible... Read more
Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
Hematuria, the presence of blood in urine, is commonly associated with bladder cancer and is its most frequent symptom. Current guidelines recommend referring patients with hematuria to urology for clinical... Read more.jpg "Image: The fastGEN BCR::ABL1 Cancer kit offers a way to personalize treatment strategies for leukemia (Photo courtesy of BioVendor MDx)")
First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
The BCR::ABL1 fusion gene plays a key role in the pathogenesis of several blood cancers, particularly chronic myeloid leukemia (CML). This gene results from a chromosomal translocation that causes constitutive... Read more
Hematology
view channel
Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more
First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
Arboviruses represent an emerging global health threat, exacerbated by climate change and increased international travel that is facilitating their spread across new regions. Chikungunya, dengue, West... Read more
POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read moreMicrobiology
view channel
Integrated Solution Ushers New Era of Automated Tuberculosis Testing
Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
Sepsis affects up to 50 million people globally each year, with bacteraemia, formerly known as blood poisoning, being a major cause. In the United States alone, approximately two million individuals are... Read more
Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more
Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
Antimicrobial resistance (AMR) is a serious global public health concern that claims millions of lives every year. It primarily results from the inappropriate and excessive use of antibiotics, which reduces... Read morePathology
view channel
New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
Many individuals have a fear of needles, making the experience of having blood drawn from their arm particularly distressing. An alternative method involves taking blood from the fingertip or earlobe,... Read more
Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more.jpg "Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)")
Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable... Read moreTechnology
view channel
New Diagnostic System Achieves PCR Testing Accuracy
While PCR tests are the gold standard of accuracy for virology testing, they come with limitations such as complexity, the need for skilled lab operators, and longer result times. They also require complex... Read more
DNA Biosensor Enables Early Diagnosis of Cervical Cancer
Molybdenum disulfide (MoS2), recognized for its potential to form two-dimensional nanosheets like graphene, is a material that's increasingly catching the eye of the scientific community.... Read more
Self-Heating Microfluidic Devices Can Detect Diseases in Tiny Blood or Fluid Samples
Microfluidics, which are miniature devices that control the flow of liquids and facilitate chemical reactions, play a key role in disease detection from small samples of blood or other fluids.... Read more
Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible
Home testing gained significant importance during the COVID-19 pandemic, yet the availability of rapid tests is limited, and most of them can only drive one liquid across the strip, leading to continued... Read moreIndustry
view channel_1.jpg "Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)")
Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
Thermo Fisher Scientific (Waltham, MA USA) has entered into a strategic distribution agreement with Bio-Techne Corporation (Minneapolis, MN, USA), resulting in a significant collaboration between two industry... Read more
ECCMID Congress Name Changes to ESCMID Global
Over the last few years, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID, Basel, Switzerland) has evolved remarkably. The society is now stronger and broader than ever before... Read more
